Investigating the effects of Vitamin E Tocotrienol on several aspects of Alzheimer’s Disease
TOCOTRIENOLS CAN SUPPORT
REDUCTION OF OXIDATIVE STRESS
REDUCTION OF CHOLESTEROL LEVELS
Introduction to Alzheimer’s Disease and TocotrienolAlzheimer’s is the 6th leading cause of death in the United States of America. There are around 5.5 million people in the US, suffering from Alzheimer’s, and around two-thirds of Americans who are suffering from this disease are women.
It has been observed that cholesterol can play a major role in causing Alzheimer’s disease and it has been observed in several studies that Tocotrienols and not Tocopherols have a good potential in lowering and reducing cholesterol levels. Tocotrienols have shown very positive results against several diseases like Stroke, Fatty liver, certain kinds of cancer, cardiovascular diseases, Alzheimer’s disease, and many more.
How does Tocotrienol fight Alzheimer’s Disease?The current treatment of Alzheimer’s Disease offers only symptomatic relief to the patients suffering. So, an agent that could help suppress the progression of dementia, which is the major characteristic of Alzheimer’s. Hence, in this study, how Tocotrienol tackles the aspects of Alzheimer’s disease were evaluated.
In the preclinical studies, it was observed that Tocotrienols reduced the oxidative stress by acting as a free-radical scavenger, promoting cellular repair, and mitochondrial function. The results of the study demonstrated that Tocotrienols also prevented glutamate-induced neurotoxicity in the brain cells.
Reference for the Study in detail:1.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073491/
2. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., et al. Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol. 2010;9:1118–1127. doi: 10.1016/S1474-4422(10)70223-4. [PubMed] [CrossRef] [Google Scholar]
3.Rosen C., Hansson O., Blennow K., Zetterberg H. Fluid biomarkers in Alzheimer’s disease—Current concepts. Mol. Neurodegener. 2013;8:20. doi: 10.1186/1750-1326-8-20. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Teipel S.J., Grothe M., Lista S., Toschi N., Garaci F.G., Hampel H. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med. Clin. N. Am. 2013;97:399–424. doi: 10.1016/j.mcna.2012.12.013. [PubMed] [CrossRef] [Google Scholar]
5. Cui Y., Liu B., Luo S., Zhen X., Fan M., Liu T., Zhu W., Park M., Jiang T., Jin J.S. Identification of conversion from mild cognitive impairment to Alzheimer’s disease using multivariate predictors. PLoS ONE. 2011;6:e21896. doi: 10.1371/journal.pone.0021896. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Sosa-Ortiz A.L., Acosta-Castillo I., Prince M.J. Epidemiology of dementia and Alzheimer’s disease. Arch. Med. Res. 2012;43:600–608. doi: 10.1016/j.arcmed.2012.11.003. [PubMed] [CrossRef] [Google Scholar]
7. Alzheimer’s Association 2015 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2015;11:332–384. [PubMed] [Google Scholar]
8. Weuve J., Hebert L.E., Scherr P.A., Evans D.A. Deaths in the united states among persons with Alzheimer’s disease (2010–2050) Alzheimers Dement. 2014;10:e40–e46. doi: 10.1016/j.jalz.2014.01.004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Wimo A., Jonsson L., Bond J., Prince M., Winblad B. The worldwide economic impact of dementia 2010. Alzheimer’s Dement. 2013;9:1–11.e13. doi: 10.1016/j.jalz.2012.11.006. [PubMed] [CrossRef] [Google Scholar]
10. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement. 2007;3:186–191. doi: 10.1016/j.jalz.2007.04.381. [PubMed] [CrossRef] [Google Scholar]
11. Kumar A., Singh A., Ekavali A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol
12. Ghezzi L., Scarpini E., Galimberti D. Disease-modifying drugs in Alzheimer’s disease.